Results 91 to 100 of about 14,494 (232)

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

HIV Medicine, EarlyView.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito, Andrea Marongiu, Antonella Cano, Mariangela Puci, Agnese Colpani, Susanna Maria Nuvoli, Maria Grazia Catte, Giulia Moi, Maria Antonietta Deledda, Sergio Uzzau, Giovanni Sotgiu, Franca Deriu, Angela Spanu, Giordano Madeddu   +13 more
wiley   +1 more source

Real‐world use of second‐generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS‐CO3‐AquiVIH‐NA cohort

HIV Medicine, EarlyView.
Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux, A. Peyrouny‐Mazeau, A. Perrier, M. Hessamfar, G. Le Moal, D. Neau, L. Alleman, C. Cazanave, E. Lazaro, P. Duffau, A. Riché, Y. Gérard, G. Barrière, S. Reigadas, M.‐A. Vandenhende, F. Bonnet   +15 more
wiley   +1 more source

Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults

Journal of the International Association of Providers of AIDS Care, 2019
Objectives and Method: There are growing concerns of tenofovir disoproxil fumarate (TDF)–associated renal toxicity. We evaluated the effect of long-term TDF exposure on renal function in a cohort of HIV-1-infected Nigerians between 2006 and 2015 ...
Oche O. Agbaji MBBS, Isaac O. Abah B.Pharm, MPH, Augustine O. Ebonyi MBBS, MSc, Zumnan M. Gimba MBBS, Esla E. Abene MBBS, Simji S. Gomerep MBBS, Kakjing D. Falang PhD, Joseph Anejo-Okopi PhD, Patricia A. Agaba MBBS, Placid O. Ugoagwu BSc, Emmanuel I. Agaba MBBS, Godwin E. Imade PhD, Atiene S. Sagay MBBS, Prosper Okonkwo MBBS, John A. Idoko MBBS, Phyllis J. Kanki DVM, DSc   +15 more
doaj   +1 more source

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir [PDF]

, 2016
OBJECTIVE: Atazanavir (ATV) and lopinavir (LPV) have been associated with kidney disease progression in HIV positive patients, with no data reported for darunavir (DRV).
Chadwick, D, Hamzah, L, Jones, R, Jose, S, Nelson, M, Phillips, A, Post, FA, Sabin, CA, Trevelion, R, Williams, DI   +9 more
core   +2 more sources

Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide

Clinical and Molecular Hepatology, 2023
Background/Aims: Tenofovir disoproxil fumarate (TDF) is known to have a lipid-lowering effect. This is in contrast to tenofovir alafenamide (TAF), which has a lipid-neutral effect. Therefore, concerns have been raised as to whether these differences affect long-term cardiovascular risk.
Hyeyeon Hong, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi   +7 more
openaire   +3 more sources

Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 8, Page 1089-1098, April 2026.
Serum HBV RNA levels at viral suppression predict HCC development in nucleos(t)ide analogue‐treated patients with chronic hepatitis B, outperforming Hepatitis B core‐related antigen alone. ABSTRACT Background Despite achieving undetectable hepatitis B virus (HBV) DNA levels with nucleos(t)ide analogue (NA) therapy, patients with chronic hepatitis B ...
Takashi Kumada, Hidenori Toyoda, Satoshi Yasuda, Yuichi Koshiyama, Takanori Ito, Tomoyuki Akita, Junko Tanaka   +6 more
wiley   +1 more source

Health care providers' decision-making and early adoption of tenofovir alafenamide for HIV preexposure prophylaxis: An inductive qualitative study.

PLoS ONE
BackgroundOver the past several years, there have been several changes affecting the available options for oral HIV preexposure prophylaxis, including approvals for tenofovir alafenamide with emtricitabine in 2019 and a generic formulation of tenofovir ...
Elisabeth Merchant, Patricia Solleveld, Kevin Gibas, Douglas Krakower   +3 more
doaj   +1 more source

Efficacy and safety of tenofovir and entecavir in patients with chronic hepatitis B-related cirrhosis: a systematic review and meta-analysis

Frontiers in Pharmacology
ObjectivesTo systematically evaluate the efficacy and safety of tenofovir and entecavir in chronic hepatitis B-related cirrhosis.MethodsA comprehensive search was conducted in databases including PubMed, Web of Science, Embase and Cochrane Library from ...
Lu Cao, Li Li, Lixing Yang, Nan Zhou, Yu Zhang   +4 more
doaj   +1 more source

Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection—General and Special Populations

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 7, Page 945-954, April 2026.
Current first‐line NUCs show comparable renal safety profiles in CHB patients with no or mild kidney dysfunction, with growing evidence that favours TAF. Future prospective studies are needed to validate these findings, and more research should focus on CHB patients with diabetes mellitus who are at risk of CKD.
Lung‐Yi Mak, Tsung‐Hui Hu, Desmond Y. H. Yap   +2 more
wiley   +1 more source

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles [PDF]

Clinical and Molecular Hepatology, 2022
Hung-Yao Lin, Tai-Chung Tseng
doaj   +1 more source